香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 為控股子公司提供擔保的進展公告》，僅供參閱。 承董事會命 证券代码：600196 股票简称：复星医药 编号：临 2025-098 上海复星医药（集团）股份有限公司 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年5 月3 0 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公 ...

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品臨床試驗進展的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年5 月3 0 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：60019 ...

Group 1 - The core viewpoint of the news highlights the positive performance of the Hong Kong pharmaceutical sector, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (930965) rising by 0.30% as of May 30, 2025, and notable increases in individual stocks such as Meizhong Jiahe (02453) up 11.32% and Fosun Pharma (02196) up 9.36% [1] - Fosun Pharma's subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received approval from the National Medical Products Administration for its new drug Luwo Mei Tini Tablets (brand name: Fumai Ning), which is indicated for treating Langerhans cell histiocytosis (LCH) and symptomatic, inoperable plexiform neurofibromas in children and adolescents with Neurofibromatosis type I (NF1) [1] - The Hong Kong Medical ETF (513700) has shown a 4.22% increase over the past week, ranking among the top in its category [1] Group 2 - The Shanghai Drug Administration is enhancing communication with the National Medical Products Administration to support enterprises in the registration and listing process, aiming to reduce obstacles and promote innovation in drug and medical device development [2] - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index comprises 50 liquid and large-cap stocks in the healthcare sector, with the top ten weighted stocks accounting for 60.54% of the index [2]

哈三联涨停， 睿智医药、 新诺威、 海南海药、 华森制药涨超5%， 复星医药、 一品红、 海王生物、 东北制药等跟涨。消息面上，国家药监局5月29日批准11款 创新药上市，相关药企昨晚统一公告。 ...

Individual Company News - Li Auto (02015.HK) reported a total revenue of 25.9 billion yuan for Q1 2025, representing a year-on-year increase of 1.1%. Adjusted net profit was 1 billion yuan, down 20.5% year-on-year [1] - Sihuan Pharmaceutical (01093.HK) is in discussions with potential partners regarding licensing and collaboration in drug development, production, and commercialization [1] - SANY International (00631.HK) achieved a net profit of 636 million yuan in Q1, a year-on-year increase of 30.6%, driven by significant revenue growth in large port machinery, oil and gas equipment, silicon energy products, and overseas mining vehicle sales [1] - Minxin Group (00222.HK) has jointly established a partnership to invest in a national-level specialized and innovative technology enterprise [1] - China Orient Group (00581.HK) reported an operating profit of approximately 199 million yuan for Q1 after deducting financial costs [1] Pharmaceutical Sector News - Jiahe Biotech (06998.HK) received approval from the Chinese National Medical Products Administration for the market launch of the new drug GB491 [2] - Fosun Pharma (02196.HK) had its registration application for the drug Luwomeitini approved by the National Medical Products Administration [2] - Yum China (09987.HK) entered into a share repurchase agreement for a total buyback amount of approximately 510 million USD for the second half of the year [2]

Group 1: Regulatory Oversight - The National Healthcare Security Administration (NHSA) is investigating potential violations related to pharmacists' credentials in retail pharmacies, with findings indicating that some pharmacists' names appear in multiple pharmacies, suggesting possible credential fraud or "hanging certificates" [1] - The investigation involves 24 provinces, 23,997 retail pharmacies, and 9,563 pharmacists, highlighting the widespread nature of the issue [1] - The NHSA has mandated self-inspections by pharmacists and comprehensive checks by pharmacies to ensure compliance and proper role fulfillment [1] Group 2: Drug Approvals - Heng Rui Medicine's new drug, injection of Rui Kang Qu Mo Zhu San, has received approval for treating adults with HER2-positive non-small cell lung cancer who have undergone at least one prior systemic therapy [3] - Te Bao Bio's long-acting growth hormone injection has been approved for treating growth hormone deficiency in children aged three and above [4] - Fosun Pharma's new small molecule cancer drug, Lu Wo Mei Ti Ni, has been approved for treating Langerhans cell histiocytosis and symptomatic neurofibromatosis type I in children and adolescents [11] Group 3: Financing Activities - Field Medical has completed a $40 million Series A financing round, aimed at advancing research and commercialization of its PFA system for treating ventricular tachycardia and atrial fibrillation [6] - Ausper Biopharma has announced a $50 million B+ financing round to support the clinical development of its innovative antisense oligonucleotide drug AHB-137 for chronic hepatitis B [7] - Ji Min Health's subsidiary has signed a strategic cooperation framework agreement with Da Bo Bio to accelerate new drug development and clinical transformation [8]

Summary of FOSUN PHARMA Conference Call Company Overview - **Company**: FOSUN PHARMA - **Industry**: Pharmaceutical and Healthcare Services Key Financial Performance - **2024 Revenue**: CNY 410.67 billion, with a significant contribution from innovative products [2][3] - **Pharmaceutical Business Revenue**: CNY 289.24 billion, up 54.83% year-on-year [2][5] - **Healthcare Services Revenue**: CNY 76 billion, up 14% year-on-year [2][7] - **Operating Cash Flow**: CNY 44.77 billion, up 31.13% year-on-year [2][3] - **Net Profit**: CNY 27.7 billion, up 16.08% year-on-year [2][3] - **R&D Investment**: CNY 55.54 billion in 2024, with CNY 36.44 billion as R&D expenses [3][5] Business Segments Performance Pharmaceutical Business - **Segment Profit**: CNY 32.50 billion, up 65.73% year-on-year [2][5] - **R&D Investment in Pharmaceuticals**: CNY 49.10 billion, accounting for 16.98% of revenue [2][5] Healthcare Services - **Segment Performance**: Loss of CNY 3 billion, but reduced loss by CNY 1 billion year-on-year [2][7][8] Medical Devices and Diagnostics - **Revenue**: CNY 43 billion, down 1% year-on-year due to decreased COVID-related product sales [6] International Expansion - **Revenue from Markets Outside Mainland China**: CNY 112.97 billion, up approximately 9% [2][13] - **Approval of Innovative Products**: PD-1 monoclonal antibody, Slurilumab, approved in the EU for extensive-stage small cell lung cancer [2][13] R&D and Clinical Progress - **New Approvals**: 7 innovative and biosimilar products with 16 indications approved [10][11] - **Clinical Trials**: 8 innovative and biosimilar products in pre-market approval and key clinical stages [11][16] Strategic Focus - **Core Areas**: Focus on innovative drugs and high-value medical devices [12][18] - **International Strategy**: Building global commercial systems and enhancing operational capabilities in overseas markets [12][13] Financial Management and Cost Control - **Cost Management**: Sales expenses down 5% and management expenses down 2% year-on-year [9] - **Debt Management**: Plans to use operating cash flow and non-core asset disposals to repay debts [9] Share Buyback Plans - **2024 Buyback**: CNY 1.27 billion for 5.68 million A-shares and HKD 0.97 billion for 7.5 million H-shares [22][23] - **2025 Buyback Plan**: Aiming to repurchase CNY 3 billion to CNY 6 billion of A-shares and up to 5% of H-shares [22][23] ESG Initiatives - **Environmental Efforts**: Investment of CNY 1.1 billion in environmental upgrades, reducing carbon emissions by 20,528 tons [24][25] - **Social Responsibility**: Over 4 million doses of self-developed artemisinin supplied globally for malaria treatment [24] Market Challenges - **Impact of Tariff Wars**: Limited direct impact on pharmaceutical exports due to cost advantages of Chinese products [19] - **Collective Procurement Policies**: Short-term revenue impacts but potential long-term benefits through improved quality and cost control [21] This summary encapsulates the key points from the FOSUN PHARMA conference call, highlighting financial performance, business segment details, international expansion, R&D progress, strategic focus, financial management, share buyback plans, ESG initiatives, and market challenges.

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司獲藥品註冊批准的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年5 月2 9 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：600196 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司獲藥品註冊批准的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年5 月2 9 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先 ...

Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration for its self-developed drug, Luwo Meitini tablets, making it the first drug in China for the treatment of adult patients with Langerhans cell histiocytosis (LCH) [1][3] Group 1: Drug Approval and Indications - Luwo Meitini tablets are approved for two indications: treatment of adult patients with LCH and treatment of symptomatic, inoperable plexiform neurofibromas (PN) in children and adolescents aged 2 years and older with Neurofibromatosis Type 1 (NF1) [3] - LCH and Erdheim-Chester disease (ECD) are rare hematological tumors, with over 80% of patients affected by multi-system involvement, leading to severe symptoms and poor prognosis due to limited effective treatment options [1] Group 2: Mechanism of Action - Luwo Meitini tablets act as a highly selective MEK1/2 inhibitor, blocking the abnormal activation of the MAPK signaling pathway, thereby inhibiting tumor cell proliferation and inducing apoptosis [1] Group 3: Ongoing Clinical Trials - Fosun Pharma is expanding the indications for Luwo Meitini tablets, with ongoing Phase III clinical trials for adult NF1 in China and Phase II trials for low-grade gliomas, extracranial arteriovenous malformations, and pediatric LCH [3]